S&P Futures
5,888.25 -4.25 (-0.07%) Dow Futures
43,046.00 -123.00 (-0.28%) Nasdaq Futures
20,518.75 -23.25 (-0.11%) Russell 2000 Futures
2,244.80 -1.40 (-0.06%) Crude Oil
72.24 +0.15 (+0.21%) Gold
2,753.60 -6.20 (-0.22%)
Medexus Pharmaceuticals Inc. (MEDXF)
| Previous Close | 1.8800 |
| Open | 1.8100 |
| Bid | 1.7800 x 40000 |
| Ask | 1.8100 x 40000 |
| Day's Range | 1.8100 - 1.8100 |
| 52 Week Range | 1.0600 - 2.3500 |
| Volume | |
| Avg. Volume | 8,785 |
| Market Cap | 44.674M |
| Beta (5Y Monthly) | 1.96 |
| PE Ratio (TTM) | 45.25 |
| EPS (TTM) | 0.0400 |
| Earnings Date | Aug 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NewsfileMedexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 19, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 7, 2024 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company's auditors.Detailed voting results for the election of di
NewsfileMedexus Provides Update on Treosulfan NDA Review Process and Extended PDUFA Goal Date
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 16, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, licensor of Medexus's commercialization rights to treosulfan, that the US Food and Drug Administration has extended the review period for the New Drug Application for treosulfan by three months. The FDA has set a new PDUFA target action date of January 30, 2025.The FDA notified medac that the Agency requires additional time ...
